17 beta-(cyclopropylamino)-androst-5-en-3 beta-ol, a selective mechanism-based inhibitor of cytochrome P450(17 alpha) (steroid 17 alpha-hydroxylase/C17-20 lyase).
A new compound, 17 beta-(cyclopropylamino)-androst-5-en-3 beta-ol, MDL 27,302, has been designed and synthesized as a mechanism-based inhibitor of cytochrome P450(17 alpha). The time-dependent inactivation of human testicular P450(17 alpha) is irreversible by dialysis and requires the cofactor, NADPH; Kiapp. 90 nM (determined on cynomolgous monkey testis enzyme). Inactivation was not affected by the nucleophile DTT, suggesting retention of the inhibitor in the enzyme active site during the inactivation process. Inhibition is specific to the cyclopropylamino compound, since the isopropylamino- and cyclobutylamino-analogs were not inhibitory. Enzymatic specificity of MDL 27,302 for P450(17 alpha) was demonstrated by its failure to inhibit steroid 21-hydroxylase and the cholesterol side chain cleavage enzyme (P450scc). Both the 17 alpha-hydroxylase and C17-20 lyase activities of cytochrome P450(17 alpha) of human testis microsomes were inhibited by MDL 27,302.
Angelastro
M R
MR
Merrell Dow Research Institute, Cincinnati, OH 45215.
Laughlin
M E
ME
Schatzman
G L
GL
Bey
P
P
Blohm
T R
TR
D000737:Androstenols / Q000494:pharmacology*; D001667:Binding, Competitive; D006801:Humans; D007700:Kinetics; D008297:Male; D008861:Microsomes / Q000201:enzymology; D009249:NADP / Q000378:metabolism; D011284:Pregnenolone / Q000378:metabolism; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*; D013250:Steroid Hydroxylases / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D013737:Testis / Q000201:enzymology
D000737:Androstenols; C060748:17-(cyclopropylamino)androst-5-en-3-ol; D009249:NADP; D011284:Pregnenolone; D013250:Steroid Hydroxylases; D013254:Steroid 17-alpha-Hydroxylase